Radboud University Medical Center: Prostatic Neoplasms trials

The registry lists 25 Prostatic Neoplasms studies with Radboud University Medical Center as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 7Phase 4 3No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Detection of Minimal Residual Disease Post-prostatectomyRecruitingNCT07334275
• Effectiveness of Focal Therapy in Men With Prostate CancerRecruitingNCT06223295Not applicable
• Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR-guided RadiotherapyNot yet recruitingNCT05373316Phase 2
• MRI-guided Focal Laser Ablation Prostate CancerRecruitingNCT05370482Not applicable
• Artificial Intelligence and Radiologists at Prostate Cancer Detection in MRI: The PI-CAI ChallengeCompletedNCT05489341
• Quantitative mpMRI to Predict Metastatic Potential of Prostate CancerStatus unknownNCT05252806
• Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223CompletedNCT04995614
• imPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGSStatus unknownNCT04746300
• 18F-PSMA-1007 PET Imaging to Detect Primary Prostate CancerCompletedNCT04487847Phase 1/2
• Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate CancerCompletedNCT04443062Phase 2
• MRI-guided Focal Laser AblationStatus unknownNCT04379362Phase 2
• Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer PatientsStatus unknownNCT04300673Phase 1/2
• F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate CancerStatus unknownNCT04239742Not applicable
• Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side EffectsCompletedNCT03927391Phase 4
• Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate CancerCompletedNCT03828838Phase 1/2
• Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.CompletedNCT03228108Phase 4
• Accuracy of Lymph Node Imaging in Prostate Cancer: PSMA PET-CT and Nano-MRIStatus unknownNCT03223064Not applicable
• Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food IntakeCompletedNCT02883166Phase 1
• Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer PatientsCompletedNCT02692976Phase 2
• Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment ResponseCompletedNCT02471469
• Optimizing Abiraterone TherapyCompletedNCT02426333
• MR-guided Focal Laser Ablation of the ProstateCompletedNCT02200809Not applicable
• Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and ToxicityCompletedNCT01621425
• Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) ApproachCompletedNCT01138527
• MR-Lymphography and Lymph Node Staging in Prostate CancerStatus unknownNCT00185029Phase 4